Graves, Alan P.

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature

Epigenetics and DNA MethylationCancer-related gene regulation

Cited by 1,786

Predicting Absolute Ligand Binding Free Energies to a Simple Model Site

Mobley, D. L., Graves, A. P., Chodera, J. D., McReynolds, A. C., Shoichet, B. K., & Dill, K. A. (2007) · Journal of Molecular Biology

Computational Drug Discovery MethodsProtein Structure and Dynamics

Cited by 310

Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor

Thomson, D. W., Poeckel, D., Zinn, N., Rau, C., Strohmer, K., Wagner, A. J., Graves, A. P., Perrin, J., Bantscheff, M., Duempelfeld, B., et al. (2019) · ACS Medicinal Chemistry Letters

interferon and immune responsesImmune Response and Inflammation

Cited by 103